Elan Restarts Phase II Alzheimer’s Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Skin-lesions issue over ACC-001 vaccine resolved with FDA.
You may also be interested in...
Start-Up Archer Preps Alzheimer’s Drugs For Phase I
IND filed, company aims to use nilvadipine derivative against soluble amyloid.
Start-Up Archer Preps Alzheimer’s Drugs For Phase I
IND filed, company aims to use nilvadipine derivative against soluble amyloid.
Wyeth Halts Alzheimer’s Trial, Drops HCV Candidate
With partner Elan, company halts ACC-001 Phase II trials after report of skin lesions.